Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
REDWOOD CITY, Calif., Feb. 03, 2016 -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on February 1, 2016, the compensation committee of the company’s board of directors granted 10 new employees options to purchase an aggregate of 17,800 shares of the company’s common stock with a per share exercise price of $18.86, the closing trading price on the grant date, and 8,900 restricted stock units. The stock options and restricted stock units were granted pursuant to the Relypsa, Inc. 2014 Employment Commencement Incentive Plan, which was approved by the company’s board of directors in June 2014 under Rule 5635(c)(4) of the Nasdaq Global Select Market for equity grants to induce new employees to enter into employment with the company.
About Relypsa, Inc.
Relypsa, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of polymeric medicines for patients with conditions that are often overlooked and undertreated and can be addressed in the gastrointestinal tract. The Company's first medicine, Veltassa™ (patiromer) for oral suspension, was developed based on Relypsa's rich legacy in polymer science. Veltassa is approved in the United States for the treatment of hyperkalemia. Veltassa has intellectual property protection until 2030 in the United States and 2029 in the European Union. More information is available at www.relypsa.com.
Contact:
Charlotte Arnold
Vice President, Corporate Communications
650.421.9352
[email protected]
